CN1218698C - 用于治疗和预防肝纤维化和肝硬化的药物组合物 - Google Patents

用于治疗和预防肝纤维化和肝硬化的药物组合物 Download PDF

Info

Publication number
CN1218698C
CN1218698C CNB018059627A CN01805962A CN1218698C CN 1218698 C CN1218698 C CN 1218698C CN B018059627 A CNB018059627 A CN B018059627A CN 01805962 A CN01805962 A CN 01805962A CN 1218698 C CN1218698 C CN 1218698C
Authority
CN
China
Prior art keywords
oltipraz
ddb
liver
fibrosis
dmn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018059627A
Other languages
English (en)
Chinese (zh)
Other versions
CN1407891A (zh
Inventor
金相建
姜建旭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1407891A publication Critical patent/CN1407891A/zh
Application granted granted Critical
Publication of CN1218698C publication Critical patent/CN1218698C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB018059627A 2000-03-02 2001-03-02 用于治疗和预防肝纤维化和肝硬化的药物组合物 Expired - Fee Related CN1218698C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10540/2000 2000-03-02
KR20000010540 2000-03-02

Publications (2)

Publication Number Publication Date
CN1407891A CN1407891A (zh) 2003-04-02
CN1218698C true CN1218698C (zh) 2005-09-14

Family

ID=36776473

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018059627A Expired - Fee Related CN1218698C (zh) 2000-03-02 2001-03-02 用于治疗和预防肝纤维化和肝硬化的药物组合物

Country Status (10)

Country Link
EP (1) EP1263435B1 (enExample)
JP (1) JP4226246B2 (enExample)
CN (1) CN1218698C (enExample)
AT (1) ATE332693T1 (enExample)
AU (1) AU2001237768A1 (enExample)
BR (1) BR0108732A (enExample)
DE (1) DE60121426T2 (enExample)
ES (1) ES2267722T3 (enExample)
RU (1) RU2250768C2 (enExample)
WO (1) WO2001064215A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030067935A (ko) * 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
KR100604261B1 (ko) * 2004-10-11 2006-07-28 재단법인서울대학교산학협력재단 신규4,5,6,7-테트라히드로-[1,2]디티올로[4,3-ｃ]피리딘-3-티온계 화합물
WO2006138507A1 (en) * 2005-06-17 2006-12-28 Novartis Ag Use of sanglifehrin in hcv
CA2651623A1 (en) 2006-05-11 2007-11-22 Patrick T. Prendergast Compositions and methods for modulating the immune system

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals

Also Published As

Publication number Publication date
EP1263435B1 (en) 2006-07-12
EP1263435A1 (en) 2002-12-11
DE60121426D1 (de) 2006-08-24
RU2002126216A (ru) 2004-03-20
AU2001237768A1 (en) 2001-09-12
ES2267722T3 (es) 2007-03-16
ATE332693T1 (de) 2006-08-15
JP2004538239A (ja) 2004-12-24
RU2250768C2 (ru) 2005-04-27
EP1263435A4 (en) 2004-08-11
BR0108732A (pt) 2002-12-17
CN1407891A (zh) 2003-04-02
WO2001064215A1 (en) 2001-09-07
JP4226246B2 (ja) 2009-02-18
DE60121426T2 (de) 2007-02-22

Similar Documents

Publication Publication Date Title
JP6605485B2 (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物
JP2021059610A (ja) 処置法
CN1901938A (zh) Dpp－iv抑制剂与抗肥胖药或食欲调节药的组合
CN102647982A (zh) 使用1,3-二苯基丙-2-烯-1-酮衍生物治疗肝脏疾患
CN1684683A (zh) Hcv丝氨酸蛋白酶的有效抑制剂
CN1192775C (zh) 吡噻硫酮在制备预防和治疗肝维化和肝硬化药物中的用途及含有其的药物组合物
CN1300214A (zh) 有效提高谷胱甘肽的吸收和协同其作用的含有肉碱和谷胱甘肽的组合物
CN1278687C (zh) 硬变肝再生的药物组合物
CN1218698C (zh) 用于治疗和预防肝纤维化和肝硬化的药物组合物
JP2005525329A (ja) 向精神薬とセレンから成る配合物
CN1604794A (zh) 滴眼剂
AU2003299772A1 (en) Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity
WO2021083912A1 (en) Combination therapy having antioxydant properties
CN1138544C (zh) 肝病治疗和预防用药物组合物
AU2010363574B2 (en) Uses of unsaturated fatty acids for inhibiting virus replication and /or infection
EP4419090A2 (en) Veratraldehyde, piperonyl alcohol, ethyl 2-amino benzoate, isoamyl cinnamate, or diethyl malonate as food additives with anti-inflammatory properties
CN1247198C (zh) 治疗高血脂症的组合物
CN1692906A (zh) 治疗高血脂症的组合物
CN1634299A (zh) 苦豆子总碱提取物在制备溃疡性结肠炎药物中的应用及结肠靶向制剂的制备方法
JP2023532840A (ja) グルココルチコイド受容体モジュレーターレラコリラントおよびｃｙｐ２ｃ９基質の併用投与
CN1644202A (zh) 葫芦素液体型组方及其制剂
JP2012006877A (ja) 認知症治療薬
CN1489464A (zh) 血液脂质改善剂组合物
CN1933835A (zh) 控制食物摄取的方法
CN1701794A (zh) 治疗高血脂症的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050914

Termination date: 20150302

EXPY Termination of patent right or utility model